Chinese Journal of Dermatology ›› 2021, Vol. 54 ›› Issue (2): 161-164.doi: 10.35541/cjd.20201028
• Perspective • Previous Articles Next Articles
Song Zhiqiang, Wang Huan
Received:
2020-10-21
Revised:
2020-12-01
Online:
2021-02-15
Published:
2021-01-29
Contact:
Song Zhiqiang
E-mail:zhiqiang.song@hotmail.com
Song Zhiqiang, Wang Huan. Advances in the treatment of atopic dermatitis: new medications, new methods and new models[J]. Chinese Journal of Dermatology, 2021, 54(2): 161-164.doi:10.35541/cjd.20201028
[1] | 中华医学会皮肤性病学分会免疫学组, 特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志, 2020,53(2):81⁃88. doi: 10.35541/cjd.20191000. |
[2] | Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis[J]. J Am Acad Dermatol, 2014,70(2):338⁃351. doi: 10.1016/j.jaad.2013.10.010. |
[3] | Ring J, Alomar A, Bieber T, et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part II[J]. J Eur Acad Dermatol Venereol, 2012,26(9):1176⁃1193. doi: 10.1111/j.1468⁃3083.2012.04636.x. |
[4] | Ahn K, Kim BE, Kim J, et al. Recent advances in atopic dermatitis[J]. Curr Opin Immunol, 2020,66:14⁃21. doi: 10.1016/j.coi.2020.02.007. |
[5] | Silverberg JI, Yosipovitch G, Simpson EL, et al. Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS[J]. J Am Acad Dermatol, 2020,82(6):1328⁃1336. doi: 10.1016/j.jaad.2020.02.060. |
[6] | Beck LA, Thaçi D, Deleuran M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open⁃label study of adults with moderate⁃to⁃severe atopic dermatitis[J]. Am J Clin Dermatol, 2020,21(4):567⁃577. doi: 10.1007/s40257⁃020⁃00527⁃x. |
[7] | de Bruin⁃Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin a or when this treatment is medically inadvisable: a placebo⁃controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ)[J]. Br J Dermatol, 2018,178(5):1083⁃1101. doi: 10.1111/bjd.16156. |
[8] | Wang C, Kraus CN, Patel KG, et al. Real⁃world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients′ records[J]. Int J Dermatol, 2020,59(2):253⁃256. doi: 10.1111/ijd.14573. |
[9] | Wollenberg A, Howell MD, Guttman⁃Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti⁃IL⁃13 mAb[J]. J Allergy Clin Immunol, 2019,143(1):135⁃141. doi: 10.1016/j.jaci. 2018.05.029. |
[10] | Pavel AB, Song T, Kim HJ, et al. Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis[J]. J Allergy Clin Immunol, 2019,144(4):1011⁃1024. doi: 10.1016/j.jaci.2019.07.013. |
[11] | Bissonnette R, Maari C, Forman S, et al. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate⁃to⁃severe atopic dermatitis: results from a randomized double⁃blind placebo⁃controlled study[J]. Br J Dermatol, 2019,181(4):733⁃742. doi: 10.1111/bjd.17932. |
[12] | Silverberg JI, Tallman AM, Ports WC, et al. Evaluating the efficacy of crisaborole using the atopic dermatitis severity index and percentage of affected body surface area[J]. Acta Derm Venereol, 2020,100(13):adv00170. doi: 10.2340/00015555⁃3489. |
[13] | Kim BS, Howell MD, Sun K, et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream[J]. J Allergy Clin Immunol, 2020,145(2):572⁃582. doi: 10.1016/j.jaci.2019.08.042. |
[14] | Nakatsuji T, Chen TH, Narala S, et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis[J]. Sci Transl Med, 2017,9(378):eaah4680. doi: 10.1126/scitranslmed.aah4680. |
[15] | Yoo J, Choi JY, Lee BY, et al. Therapeutic effects of saline groundwater solution baths on atopic dermatitis: a pilot study[J]. Evid Based Complement Alternat Med, 2020,2020:8303716. doi: 10.1155/2020/8303716. |
[16] | Maarouf M, Shi VY. Bleach for atopic dermatitis[J]. Dermatitis, 2018,29(3):120⁃126. doi: 10.1097/DER.0000000000000358. |
[17] | Fishbein AB, Lor J, Penedo FJ, et al. Patient⁃reported outcomes for measuring sleep disturbance in pediatric atopic dermatitis: cross sectional study of PROMIS pediatric sleep measures and actigraphy[J]. J Am Acad Dermatol, 2020,S0190⁃9622(20)31015⁃X. doi: 10.1016/j.jaad. 2020.05.138. |
[18] | Gustafson CJ, O′Neill J, Hix E, et al. Feasibility of actigraphy wristband monitoring of atopic dermatitis in children[J]. Skin Res Technol, 2014,20(4):510⁃514. doi: 10.1111/srt.12147. |
[19] | Dong B, Ren A, Shah SA, et al. Monitoring of atopic dermatitis using leaky coaxial cable[J]. Healthc Technol Lett, 2017,4(6):244⁃248. doi: 10.1049/htl.2017.0021. |
[20] | Eto H, Tsuji G, Chiba T, et al. Non⁃invasive evaluation of atopic dermatitis based on redox status using in vivo dynamic nuclear polarization magnetic resonance imaging[J]. Free Radic Biol Med, 2017,103:209⁃215. doi: 10.1016/j.freeradbiomed.2016.12. 043. |
[21] | Wenninger K, Kehrt R, von Rüden U, et al. Structured parent education in the management of childhood atopic dermatitis: the Berlin model[J]. Patient Educ Couns, 2000,40(3):253⁃261. doi: 10.1016/s0738⁃3991(99)00074⁃9. |
[22] | van Os⁃Medendorp H, Deprez E, Maes N, et al. The role of the nurse in the care and management of patients with atopic dermatitis[J]. BMC Nurs, 2020,19(1):102. doi: 10.1186/s12912⁃020⁃00494⁃y. |
[23] | 赖沙, 王华. 特应性皮炎治疗中的患者教育和管理[J]. 国际皮肤性病学杂志, 2013,39(4):255⁃257. doi: 10.3760/cma.j.issn. 1673⁃4173.2013.04.014. |
[24] | 蒲晓英. 全程健康教育对银屑病患者生活质量的影响[J]. 中国医疗前沿, 2013,(10):110⁃111. doi: 10.3969/j.issn.1673⁃5552. 2013.10.0082. |
[1] | Zhang Ning, Li Shu, Li Jing . Efficacy of immune checkpoint inhibitors and targeted therapy in adjuvant treatment of resectable melanoma: a network meta-analysis [J]. Chinese Journal of Dermatology, 2022, 0(4): 20200767-e20200767. |
[2] | Liu Yuzhen, Zeng Rong, Zheng Nana, Duan Zhimin, Xu Haoxiang, Wu Qiuju, Lin Tong, Li Min. Effect of different incubation time of aminolevulinic acid on photodynamic inhibition of Propionibacterium acnes biofilms [J]. Chinese Journal of Dermatology, 2022, 55(3): 208-212. |
[3] | Writing committee expert group on “diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement”. Diagnosis and treatment of pustular psoriasis: a Chinese expert consensus statement (2022) [J]. Chinese Journal of Dermatology, 2022, 55(3): 187-195. |
[4] | Wen Guangdong, Mao Dandan, Zhang Yuanyuan, Dou Yuanqing, Zhao Pei, Wu Chenyu, Zhang Jianzhong. A case of generalized lichen amyloidosis treated with dupilumab: the first case reported in China [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210694-e20210694. |
[5] | Ou Min, Yan Yunling, Zheng Baoqing, Wang Xiaohua. Correlations between psoriasis and obesity [J]. Chinese Journal of Dermatology, 2022, 55(2): 181-184. |
[6] | Bao Shijie, Cheng Yang, Yan Ying, Fan Fang, Gao Tingting, Feng Xiaolan, Zheng Liang, Lei Wei, Huang Qinsi, Zhang Weiming, Zhou Xiaoyong. A comparative study of human immunoglobulin versus recombinant human tumor necrosis factor-α receptor Ⅱ:IgG Fc fusion protein in the treatment of toxic epidermal necrolysis [J]. Chinese Journal of Dermatology, 2022, 55(2): 153-156. |
[7] | Li Sai, Xue Huazhong, Zhang Shuwen, Jiang Juan, Qi Shuzhen, Zhao Yuanyuan, Zhang Jinping, Sha Zhong, Le Wenjing, Wang Biwei, Zhao Shixuan, Zhu Xiaofeng, Su Xiaohong. Doxycycline-moxifloxacin sequential therapy for Mycoplasma genitalium urethritis/cervicitis: a clinical observation [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210631-e20210631. |
[8] | Jiao Xiaoyan, Yin Guangwen, Yin Yakun, Li Dongqin. Clinical analysis of 25 cases of herpes zoster during pregnancy or the perinatal period [J]. Chinese Journal of Dermatology, 2022, 0(2): 20210384-e20210384. |
[9] | Chinese Society of Dermatology, China Dermatologist Association. Consensus on the diagnosis and treatment of autoimmune subepidermal bullous diseases (2022) [J]. Chinese Journal of Dermatology, 2022, 55(1): 1-11. |
[10] | Luan Chao, Hu Yu, Chen Kun, Zhang Jiaan, Gu Heng, Zhang Ronglin, Zhang Xiaohua, Tian Panpan, Zhu Yan, Zhuang Chen, Huang Dan, Ju Mei. Efficacy and safety of 308-nm SQ light-emitting diode light and 308-nm excimer light in the treatment of facial vitiligo: a retrospective study [J]. Chinese Journal of Dermatology, 2022, 55(1): 16-19. |
[11] | Guo Jing, Yang Jingyu, Ding Li, Liu Mingming, Hou Jingmei, Pu Xiaoxia, Sun Jiayu, Li Xianghua. Efficacy of long-pulsed 1 064-nm Nd:YAG laser combined with a topical emulsion containing Camellia reticulata and Radix Notoginseng in the treatment of melasma [J]. Chinese Journal of Dermatology, 2022, 55(1): 61-64. |
[12] | Cao Meng, Hong Anlan, Wang Yan, Fang Fang. Clinical progress in pediatric melanoma [J]. Chinese Journal of Dermatology, 2022, 0(1): 20210158-e20210158. |
[13] | Li Yue, Wu Jinyan, Yuan Ruoyue, Yang Quyang, Zhao Xiansheng, Zhu Ningwen. Cell therapy for hereditary epidermolysis bullosa [J]. Chinese Journal of Dermatology, 2022, 0(1): 20201116-e20201116. |
[14] | Qiu Yueqi, Fu Siqi, Luo Shuaihantian, Li Yaping, Zhang Guiying. Research advance in androgenetic alopecia in 2020 [J]. Chinese Journal of Dermatology, 2021, 54(9): 835-838. |
[15] | Autoimmune Disease Group, China Dermatologist Association. Chinese expert consensus on cyclophosphamide for the treatment of autoimmune dermatoses [J]. Chinese Journal of Dermatology, 2021, 54(9): 765-770. |
|